UNC0379

Research use only, not for human use.

UNC0379 is a selective, substrate-competitive inhibitor of lysine methyltransferase SETD8 with IC50 of 7.3 uM.

UNC0379 is a selective, substrate-competitive inhibitor of lysine methyltransferase SETD8 with IC50 of 7.3 uM, displays good selectivity over 15 other methyltransferases, including G9a and GLP (IC50>100 uM); causes neuroblastoma (NB) cell growth inhibition which is p53 dependent, reduces levels of p53K382me1 modification in xenografts.

UNC0379 (1-10 μM, 9 days) inhibits HGSOC cells proliferation.?UNC0379 (10 μM, 96 h) increases in the proportion of sub-G1 phase cells in HGSOC cells.UNC0379 (10 μM, 48 h) induces myofibroblast de-differentiation and inhibits additional fibroblast to myofibroblast differentiation. Cell Viability Assay Cell Line:JHOS2, JHOS3, JHOS4, OVCAR3, OVCAHO, OVKATE, KURAMOCHI, TYKnu Concentration:1-10 μM Incubation Time:9 days Result:Inhibited HGSOC cells proliferation with IC50s ranging from 0.39 to 3.20 μM.Cell Cycle Analysis Cell Line:JHOS3, OVCAR3 Concentration:10 μM Incubation Time:96 hResult:Arrested cells in sub-G1 phase.

UNC0379 (intratracheal administration, 1 mg/kg/day, on day7, 8, and 9) ameliorates the lung fibrosis in Bleomycin (BLM)-induced lung fibrosis mouse. Animal Model:Bleomycin (BLM)-induced lung fibrosis mouse modelDosage:1 mg/kg/day Administration:Intratracheal administration, on day7, 8, and 9.Result:Ameliorated BLM-induced lung fibrosis (supported by the evaluation of the Ashcroft score and changes in the collagen content in the lung samples) without affecting pulmonary inflammation.

UNC 0379 | UNC-0379

Chromatin/Epigenetic

HMTase

SETD8

Other Indications

——

1620401-82-2

413.5563

C23H35N5O2

>98% (HPLC)

10 mM in DMSO

COC1=C(OC)C=C(N=C(N2CCCC2)N=C3NCCCCCN4CCCC4)C3=C1

4-Quinazolinamine, 6,7-dimethoxy-2-(1-pyrrolidinyl)-N-[5-(1-pyrrolidinyl)pentyl]-

(-20℃)

With Ice Pack

≥ 2 years